pulmicort and Esophageal-Neoplasms

The most important novel findings presented on oesophageal disease in DDW 2015 were the following: 1) GERD: a) hypervigilance seems to be a key pathogenic factor in reflux symptoms refractory to PPI; b) post-reflux swallowing-induced peristaltic waves could be an excellent diagnostic criterion for GERD; c) laryngeal pH-metry is not useful in the diagnosis of extra-oesophageal symptoms; d) the recommendation of weight loss adequately recorded in the clinical reports of patients with GERD and obesity or overweight is an excellent quality indicator and is associated with better outcomes. 2) Barrett's oesophagus: a) persistent low-grade dysplasia in more than one endoscopy and a diagnosis of "indefinite for dysplasia" are associated with a high risk of neoplastic progression; b) narrow-band imaging allows areas of dysplasia on Barrett's oesophagus to be identified with high sensitivity and specificity; c) initial endoscopy fails to identify a high percentage of advanced neoplasms in Barrett's oesophagus. Early re-endoscopy should be considered; d) endoscopists specialized in Barret's oesophagus obtain a much higher yield in the diagnosis of advanced lesions. Patients at high risk-men, older patients, smokers and those with long-segment Barrett's oesophagus-could benefit from follow-up in a referral center. 3) Achalasia: POEM seems safe and effective, independently from patient characteristics (age, comorbidity) and the technical variations used. 4) Eosinophilic esophagitis: topical budesonide and exclusion diets are reasonably effective in PPI non-responders.

Topics: Anxiety; Barrett Esophagus; Budesonide; Clinical Trials as Topic; Disease Progression; Eosinophilic Esophagitis; Esophageal Achalasia; Esophageal Diseases; Esophageal Neoplasms; Esophagoscopy; Gastroesophageal Reflux; Humans; Meta-Analysis as Topic; Pulsed Radiofrequency Treatment; Weight Loss

EMR and endoscopic submucosal dissection (ESD) are treatment modalities for Barrett's esophagus involving high-grade dysplasia or early cancer. Injectional corticosteroid therapy decreases the risk of procedure-related esophageal stricture (ES) formation. Our aim was to assess the efficacy of topical budesonide on the rate of ES formation after EMR or ESD.. Patients included prospectively from 3 tertiary endoscopy centers received 3 mg budesonide orally twice a day for 8 weeks after esophageal EMR or ESD of 50% or more of the esophageal circumference between January 1, 2014 and June 30, 2018. These patients were matched (1:3 ratio) retrospectively with a consecutive patient cohort who underwent EMR or ESD of 50% or more of the esophageal circumference without concomitant corticosteroid therapy. The primary endpoint was the presence of ES at the 12-week follow-up.. Twenty-five patients (budesonide) were matched with 75 patients (no budesonide). Most underwent EMR for Barrett's esophagus with biopsy-proven high-grade dysplasia or suspected T1a cancer. Although most baseline characteristics did not differ significantly, patients in the budesonide cohort tended to have a higher proportion of circumferential EMR. The proportion of patients with ES was not significantly lower in the budesonide cohort (16% vs 28%). On logistic regression analysis, budesonide remained associated with a lower incidence of ES (P = .023); however, when controlling for baseline characteristics with a propensity score weighted logistic regression model, there was no significant effect on ES formation (P = .176).. Topical budesonide might be associated with a reduction of ES after EMR or ESD; however, further studies are needed to verify our results.

Topics: Adenocarcinoma; Barrett Esophagus; Budesonide; Endoscopic Mucosal Resection; Esophageal Neoplasms; Esophageal Stenosis; Humans; Retrospective Studies

 Endoscopic resection is the treatment of choice for early esophageal cancers. However, resections comprising more than 70-80 % of the circumference are associated with a high risk of stricture formation. Currently, repetitive local injections and/or systemic steroids are given for prevention..  We present here the case of a 78-year-old male patient who had a near circumferential endoscopic submucosal dissection for a pT1a mm, L0, V0, R0, G2 esophageal squamous cell cancer. At the end of endoscopic resection, 80 mg of triamcinolone was injected locally. The patient was then treated with oro-dispersible budesonide tablets (2 × 1 mg/day) and nystatin (4 × 100 000 I.E.) for 8 weeks. This treatment resulted in complete healing without any stricture formation and did not result in any complications..  Treatment with orodispersible budesonide tablets could help prevent strictures after large endoscopic resections in the esophagus..  Die endoskopische Resektion von Ösophagusfrühkarzinomen ist der aktuelle Therapiestandard. Allerdings sind Resektionen von mehr als 70–80 % der Zirkumferenz mit einem sehr hohen Strukturrisiko behaftet. Aktuell werden zur Prävention wiederholte lokale Steroidinjektionen und/oder systemische Steroide eingesetzt..  Wir berichten über einen 78-jährigen Mann, bei dem wegen eines Plattenepithelfrühkarzinoms (pT1a mm, L0, V0, R0, G2) eine subtotal zirkumferentielle endoskopische Submukosadissektion durchgeführt worden war. Am Ende der Resektion wurde einmalig 80 mg Triamcinolon lokal injiziert. Anschließend wurde über 8 Wochen mit oro-dispersiblen Budesonid Tabletten (2 × 1 mg) und Nystatin (4 × 100 000 I.E.) behandelt. Diese Therapie führte zu einer kompletten Ausheilung ohne Ausbildung einer Striktur. Komplikationen wurden nicht beobachtet..  Die Therapie mit orodispersiblen Budesonid Tabletten könnte zur Prävention von Strikturen nach ausgedehnten endoskopischen Resektionen im Ösophagus hilfreich sein.

Topics: Aged; Budesonide; Carcinoma, Squamous Cell; Constriction, Pathologic; Esophageal Neoplasms; Esophageal Stenosis; Esophagoscopy; Humans; Male; Postoperative Complications; Tablets

Complete endoscopic resection (CER) of short-segment Barrett's esophagus with high grade dysplasia (HGD) and early esophageal adenocarcinoma (EEA) is a precise staging tool and achieves durable disease control. The major drawback is development of post-endoscopic resection esophageal stricture (PERES). No effective therapy to prevent PERES has been described. Viscous budesonide slurry (VBS) may have a role in the prevention of PERES by suppressing the post-CER inflammatory process. The study aim was to evaluate the efficacy of VBS for the prevention of PERES.. Prospective data were collected on patients referred for CER of HGD or EEA. After January 2012, patients routinely received VBS (two 0.5-mg/2-mL budesonide respules mixed with sucralose) twice daily for 6 weeks following each stage of the CER schedule. All patients received high dose proton pump inhibitor therapy for the duration of CER and the following 3 months. Patients had no other intervention to prevent PERES. A validated dysphagia score was used (0 - 4, no dysphagia to aphagia). Endoscopic dilation was performed for dysphagia. Patients receiving VBS were compared with historical controls. The primary endpoint was the need for dilation.. Between January 2008 and January 2015, 104 of 116 eligible patients completed CER. The VBS group (n = 29) and non-VBS group (n = 75) had similar patient, disease, and procedural characteristics. Dilations were needed in 13.8 % vs. 37.3 % (P = 0.03), with a median of one vs. two procedures (P = 0.01), and median dysphagia score during CER of 0 vs. 1 (P = 0.02) in the VBS and non-VBS groups, respectively. No VBS-related adverse events were noted.. In this pilot study VBS significantly reduced PERES and shortened the dilation program after CER.

Topics: Adenocarcinoma; Adult; Aged; Anti-Inflammatory Agents; Barrett Esophagus; Budesonide; Drug Administration Schedule; Esophageal Neoplasms; Esophageal Stenosis; Esophagoscopy; Female; Follow-Up Studies; Humans; Male; Middle Aged; Pilot Projects; Postoperative Complications; Precancerous Conditions; Prospective Studies; Treatment Outcome; Viscosity